# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0000886163-18-000084
Filing Date
2018-06-27
Accepted
2018-06-27 16:08:21
Documents
6
Period of Report
2018-06-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | ligand-form8xkrewuxiamendm.htm | 8-K | 26307
2 | EXHIBIT 99.1 | a20180627ligandreceives4.htm | EX-99.1 | 11575
3 |  | a20180627ligandreceives4001.jpg | GRAPHIC | 266852
4 |  | a20180627ligandreceives4002.jpg | GRAPHIC | 281999
5 |  | a20180627ligandreceives4003.jpg | GRAPHIC | 342276
6 |  | a20180627ligandreceives4004.jpg | GRAPHIC | 46398
| Complete submission text file | 0000886163-18-000084.txt |  | 1330889

Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 18921894
SIC: 2834 Pharmaceutical Preparations